Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 3/20 | 0.36 |
| ▸ | VDR | P11473 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL450129 | 1.00 | CYP2D6 (0.39) | CYP2D6CYP3A4TSHRALDH1A1CYP2C9 | |
| SCHEMBL15878904 | 1.00 | CYP2D6 (0.39) | CYP2D6CYP3A4TSHRALDH1A1CYP2C9 | |
| SCHEMBL17823577 | 0.81 | ALDH1A1 (0.37) | CYP2D6CYP3A4TSHRALDH1A1CYP2C9 | |
| SCHEMBL3632337 | 0.81 | ALDH1A1 (0.37) | CYP2D6CYP3A4TSHRALDH1A1CYP2C9 | |
| SCHEMBL17832663 | 0.81 | ALDH1A1 (0.37) | CYP2D6CYP3A4TSHRALDH1A1CYP2C9 | |
| SCHEMBL9701624 | 0.81 | GAA (0.43) | CYP2D6CYP3A4TSHRALDH1A1CYP2C9 | |
| SCHEMBL1776287 | 0.80 | CRBN (0.40) | CYP2D6CYP3A4TSHRALDH1A1CYP2C9 | |
| SCHEMBL31309789 | 0.77 | IRAK4 (0.36) | IRAK4KMT2A | |
| SCHEMBL6414324 | 0.77 | LMNA (0.38) | CYP2D6CYP3A4TSHRALDH1A1CYP2C9 | |
| SCHEMBL3214114 | 0.76 | LMNA (0.37) | IRAK4MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074890-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-03-06 | — | — | US | disclosed |
| WO-2024220399-A1 | PYRAZOLOTRIAZINECARBONITRILES USEFUL AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-10-24 | — | — | WO | disclosed |
| EP-4380919-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | Dana-Farber Cancer Institute, Inc. (US) | 2024-06-12 | — | — | EP | disclosed |
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | JANSSEN RESEARCH & DEVELOPMENT, LLC | 2024-05-16 | — | — | US | disclosed |
| EP-4284801-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | Janssen Biotech, Inc. (US) | 2023-12-06 | — | — | EP | disclosed |
| WO-2023015164-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-02-09 | — | — | WO | disclosed |
| CN-110183433-B | Pyrazole compound and preparation method and application thereof | 华东理工大学 | 2021-06-04 | — | — | CN | disclosed |
| EP-2776435-B1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LTD (GB) | 2018-06-27 | — | — | EP | disclosed |
| US-10004733-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| EP-2941427-B1 | NOVEL BENZODIOXANE-PIPERIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS | PF MEDICAMENT (FR) | 2016-11-09 | — | — | EP | disclosed |
| WO-2009001132-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| WO-2007048595-A1 | COMPOUNDS COMPRISING A LACTAM OR A LACTAM DERIVATIVE MOIETY, PROCESSES FOR MAKING THEM, AND THEIR USES | UCB PHARMA, S.A. (BE) | 2007-05-03 | — | — | WO | disclosed |
| EP-1027051-B1 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2005-01-05 | — | — | EP | disclosed |
| US-6391901-B1 | Thrombin inhibitors | ELI LILLY AND COMPANY | 2002-05-21 | — | — | US | disclosed |
| EP-1027051-A4 | ANTITHROMBOTIC AGENTS | LILLY CO ELI (US) | 2001-03-07 | — | — | EP | disclosed |
| EP-1027051-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 2000-08-16 | — | — | EP | disclosed |
| WO-1998048804-A1 | ANTITHROMBOTIC AGENTS | ELI LILLY AND COMPANY (US) | 1998-11-05 | — | — | WO | disclosed |
| EP-0138539-B1 | 2-AZACYCLOALKYLTHIOPENEM DERIVATIVES | PFIZER INC. (US) | 1989-03-15 | — | — | EP | disclosed |
| US-4772597-A | ANTIBIOTICS | PFIZER INC. (US) | 1988-09-20 | — | — | US | disclosed |
| EP-0138539-A1 | 2-Azacycloalkylthiopenem derivatives | PFIZER INC. (US) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004733-B2 | — | SDHB, SDHA, NDUFS5 | CYP2D6 27/4885CYP3A4 93/4885TSHR 3445/4885 |
| US-20240158392-A1 | SMALL MOLECULE INHIBITORS OF SALT INDUCIBLE KINASES | SIK2, SIK1, SGK2 | CYP2D6 4759/4885CYP3A4 4777/4885TSHR 4262/4885 |
| US-20250074890-A1 | CYANOPYRIDINE AND CYANOPYRIMIDINE BCL6 DEGRADERS | BCL6, BCL6B, BCOR | CYP2D6 969/4885CYP3A4 1903/4885TSHR 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.